Taiwan's TaiMed Biologics Inc. has made the first approval filing for its novel antibody treatment ibalizumab for use in multi-drug resistant HIV in the US, where it is licensed to Theratechnologies Inc. If successful, it would be the first new antiretroviral with a novel mode of action for nearly a decade, and the first that would not require daily dosing.
The submission is based on data from the Phase III TMB-301 study, a single arm, 24-week study of ibalizumab given...







